FDA Uses "Unusual" Action To Get Matrixx's Zicam Off The Market
This article was originally published in The Tan Sheet
Executive Summary
In a rare action, FDA simultaneously alerted consumers not to use Matrixx Initiatives' intranasal Zicam products because of potential safety problems and warned Matrixx to remove the products from market without first consulting with the firm